Brief Communication

Treatment of multiple sclerosis with an anti–interleukin-2 receptor monoclonal antibody

  1. John W. Rose MD1,2,*,
  2. Hilary E. Watt BS1,2,
  3. Andrea T. White PhD1,3,
  4. Noel G. Carlson PhD1,4,5

Article first published online: 20 OCT 2004

DOI: 10.1002/ana.20287

Issue

Annals of Neurology

Annals of Neurology

Volume 56, Issue 6, pages 864–867, December 2004

Additional Information

How to Cite

Rose, J. W., Watt, H. E., White, A. T. and Carlson, N. G. (2004), Treatment of multiple sclerosis with an anti–interleukin-2 receptor monoclonal antibody. Ann Neurol., 56: 864–867. doi: 10.1002/ana.20287

Author Information

  1. 1

    Neurovirology Research Laboratory, VA Salt Lake City Health Care System

  2. 2

    Department of Neurology, University of Utah

  3. 3

    Department of Exercise and Sport Science, University of Utah

  4. 4

    Department of Geriatrics, Research and Clinical Center, VA Salt Lake City Health Care System

  5. 5

    Neurobiology and Anatomy, University of Utah, Salt Lake City, UT

*Neurovirology Research Laboratory (151B), VASLSHCS, 500 Foothill Drive, Salt Lake City, UT 84148

Publication History

  1. Issue published online: 23 NOV 2004
  2. Article first published online: 20 OCT 2004
  3. Manuscript Revised: 12 AUG 2004
  4. Manuscript Accepted: 12 AUG 2004
  5. Manuscript Received: 10 JUN 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (97K)

Abstract

We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin-2 receptor α chain, was safe and efficacious in relapsing–remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity. Ann Neurol 2004

View Full Article (HTML) Get PDF (97K)